CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 3 enrolled
Drug / intervention
OCL 503 (uterine artery embolization)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02410018
NCT02410018N/ACompleted
CompareCT.gov

An Open Label, Single Center, Pilot Study to Evaluate the Safety and Effectiveness of OCL 503 in the Treatment of Women With Leiomyomata Scheduled for Hysterectomy

IMBiotechnologies Ltd.·interventional·Posted Apr 7, 2015·Updated Dec 5, 2018

In Brief

A clinical study evaluating OCL 503 (uterine artery embolization) for Leiomyomata. Completed, enrolled 3 participants across 1 site.

Detailed Summary

This is a prospective, pilot, open-label, uncontrolled, safety and effectiveness study of uterine artery embolization with OCL 503 in women with leiomyomata who are scheduled for hysterectomy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeiomyomata
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 7, 2015
Enrollment StartApr 1, 2015
Primary CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 11.2 years ago

Interventions

OCL 503 (uterine artery embolization)device

Transcatheter embolization of the uterine artery(ies) using an embolic agent.